Quebec City, June 12, 2025 – Aramis Biotechnologies Inc. (“Aramis”), a Quebec City-based company specialized in plant-based biomanufacturing of innovative vaccines, proudly announces a series of groundbreaking advancements, unveiled at the first Annual Aramis Scientific Horizon. Achieved within just 12 months, these milestones underscore Aramis’ commitment to rapid, high-impact innovation and mark a major leap forward for Aramis, with transformative implications for both plant-based production and commercialization of Aramis’ first product.
Key Scientific Milestones:
- Multifold Increase in Productivity
Aramis’ next-generation platform has achieved a multifold increase in plant-based protein productivity, setting a new industry benchmark.
- Next-Generation Closed Plant Production System
By replacing traditional greenhouses with a proprietary controlled-environment production system, Aramis has enhanced control, reproducibility, and biomass quality—allowing exportability anywhere in the world. - Streamlined Commercial Scale-Up
The new high-yielding platform eliminates the need for scale-up in commercial production, accelerating timelines and reducing costs. - Promising Preclinical Vaccine Results
Aramis’ next-generation Virus-Like Particle (VLP) seasonal influenza vaccine candidate has shown favorable outcomes in preclinical studies compared to current market alternatives.
“Aramis was founded with a clear vision: to build a robust, scalable platform that accelerates the path from scientific discovery to commercial products. With today’s results, our vision is becoming reality, said Mr. Frédéric Ors, Aramis’ Chief Executive Officer.
“The exceptional yields obtained mean that the current clinical-scale process used by Aramis for clinical studies, which complies with Good Manufacturing Practices (GMP), is already sufficient to support a commercial vaccine launch—eliminating the need for scaling up. In the world of bioproduction, this is a decisive advantage and a significant victory.”
Dr. Marc-André D’Aoust, Aramis’ Chief Scientific Officer, added: “Virus-Like Particles are among the most effective vaccine technologies, mimicking natural immunization without live pathogens. While VLPs have demonstrated commercial success, manufacturing hurdles have limited their broader application. Our plant-based platform removes critical barriers, unlocking the full potential of VLP vaccines for influenza.”
“Our influenza vaccine candidate is designed to address a significant unmet medical need in protecting vulnerable populations against influenza—especially the elderly— by enhancing protection duration and improving the immune response,” Dr. D’Aoust continued. “We eagerly anticipate the launch of our comparative Phase 1 and 2 clinical trials in Q1 2026.”
About Aramis Biotechnologies
Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, Aramis’ ambition is to develop innovative and sustainable solutions to current and future public health challenges. The Aramis’ team is grateful for the support from Innovation, Sciences and Economic Development Canada, from the City of Quebec and from its group of private investors. For more information: aramisbiotechnologies.com